Spots Global Cancer Trial Database for Real World Study of Four PD-1 Agents in China
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Real World Study of Four PD-1 Agents in China
Official Title: Real World Study of Immunotherapy-Comparison of Four PD-1 Agents in China
Study ID: NCT03966456
Interventions
Study Description
Brief Summary: Consecutive patients treated with PD-1 therapy in Qingdao City were included in our study. The effecy and safety of the four PD-1 agents according to clinical outcomes in real world will be studied.
Detailed Description: Consecutive patients treated with PD-1 therapy in Qingdao City were included in our study. The effecy and safety of the four PD-1 agents according to clinical outcomes in real world will be studied. ORR will be studied of the four PD-1 agents（nivolumab, pembrolizumab, toripalimab, sintilimab）
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
Contact Details
Name: Xiaochun Zhang, Dr
Affiliation: The Affiliated Hospital of Qingdao University
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
